Imbruvica, a cancer medication, carries a wholesale price of about $16,000 a month. Patients on Medicare who don’t qualify for low-income subsidies could see out-of-pocket costs for the drug of over $12,000. Isn’t it time for Congress to finally pass legislation that helps patients?
Cancer drugs
KEY TAKEAWAY: Few cancer drugs approved via the accelerated FDA approval pathway were judged to have verified benefits based on improvement in survival reported in confirmatory trials.